DOVE | APGOT-OV7/ENGOT-ov80

The DOVE trial is a Phase II, randomised study evaluating the efficacy and safety of dostarlimab alone or with bevacizumab versus nonplatinum chemotherapy in recurrent gynaecological clear cell carcinoma.

DOVE | APGOT-OV7/ENGOT-ov802025-09-11T16:18:58+10:00

RAMP-301 | NCT06072781

The RAMP-301 trial will assess the safety and efficacy of the combination of Avutometinib plus Defactinib versus Investigator’s Choice of Treatment options (ICT) in patients with recurrent Low-grade Serous Ovarian Cancer (LGSOC) who have progressed on a prior platinum-based [...]

RAMP-301 | NCT060727812024-07-19T11:32:01+10:00

EN.10/TAPER | NCT05640999

The primary objective of this study is to estimate the rate of pelvic recurrence at 3 years in patients who are treated with de-escalated adjuvant treatment directed by tumour molecular status.

EN.10/TAPER | NCT056409992024-07-09T16:59:38+10:00

DOMENICA | NCT05201547

The primary objective of this study is to evaluate progression-free survival (PFS) by blinded independent central review (BICR) in patients treated in a first line setting with chemotherapy (paclitaxel and carboplatin) versus dostarlimab.

DOMENICA | NCT052015472024-07-09T16:59:53+10:00

PEACE | ACTRN12621001031853

PEACE aims to determine the feasibility of collecting information from women, and their careers, with advanced gynaecological cancer about their experiences, satisfaction with care and symptom management towards end of life. Information collected focuses on how both patients and [...]

PEACE | ACTRN126210010318532024-07-09T17:00:33+10:00

PARAGON-II | ACTRN12621000639820

PARAGON-II is a trial investigating whether a combination of two drugs (letrozole with alpelisib or letrozole with ribociclib) is an active treatment for a range of advanced gynaecological cancers that expresses hormone receptors.

PARAGON-II | ACTRN126210006398202024-07-09T17:00:40+10:00

ADELE | ACTRN12621000273886

ADELE is a randomised phase 2 trial testing the effect of ADjuvant tislelizumab plus chemotherapy after post-operative pelvic chemoradiation in high risk EndometriaL cancer.  

ADELE | ACTRN126210002738862024-07-09T17:00:50+10:00
Go to Top